Renal Cancer Drug Market Share

Global Renal Cancer Drugs Market Overview

Renal Cancer Drugs Market Size was valued at USD 3.72 Billion in 2023. The Global Renal Cancer Drugs industry is projected to grow from USD 4.73 Billion in 2024 to USD 8.48 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.12% during the forecast period (2024 - 2032).

Renal cancer also called as kidney cancer or hypernephroma. Renal cancer is a disease in which kidney cells become malignant, the cells start proliferating out of control and start forming a tumor. Principal locations for kidney cancer are renal tube and renal pelvis. It is observed both in males and females between the age group of 50 to 80 years. 

The key factors responsible for influencing renal cancer drugs market are increasing use of tobacco, smoking, and increasing alcohol consumption which can also lead to cause renal cancer. Other factors of renal cancer drugs market which support to cause renal cancer are obesity and mutation in von Hippel-Lindau (VHL) gene. According to the World Cancer Research Fund, 2018 database has estimated kidney cancer is the ninth most commonly occurring cancer in men and 14th most commonly occurring cancer in women. According to the American Cancer Society in 2018, 63,340 new cases of kidney cancer are estimated in the US This is expected to provide favorable backgrounds for the renal cancer drugs market growth during the forecast period.

However, factors such as the high cost of expensive chemotherapy, increasing preference for generic drugs and side effects associated with drugs are expected to restrict the renal cancer drugs market growth during the forecast period.

The U.S. Food and Drug Administration (FDA) approved Mounjaro™ (tirzepatide) injection as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes, a GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist made by Eli Lilly and Company's (NYSE: LLY), May 2022. It should not be used in patients with type one diabetes mellitus since there are no studies carried out on it for pancreatitis history patients. which is the first FDA-approved GIP & GLP-1 agonist that acts on GIP and GLP-1 receptors found naturally within the body called incretins.

On January 2023, Everimmune said it had treated its first patient as part of a phase one clinical trial involving lung and kidney cancer patients studying Oncobax AK. The study aims to evaluate how effective Oncobax AK can be used together with immunotherapy treatment, as well as its toxicity. In addition, for this trial, EverImmune intends to enroll 60 people: 41 for renal cell carcinoma (RCC) and 19 for non-small cell lung cancer (NSCLC), spanning phases I & IIa, using four sites based in France or Belgium. Phase I results will be available by H1-end. At the same time, approvals were based on data from the SURPASS program phase III with active comparators – Injectable Semaglutide 1mg, Insulin degludec, and Insulin glargine, which included several compounds like Mounjaro.

As we approach the end of this year, Eli Lilly puts forth its plan for the year ahead before the biopharma industry enters into a lull of the Christmas holidays. For example, next year, Lilly intends to file five regulatory applications along with six phase III trials initiation and present data from 6 additional phase III trials, according to executives at the investor presentation on Tuesday. With that said and done, new approvals alongside diabetes breakthroughs such as Mounjaro are projected to help the firm make sales worth $30 billion next year, as said by execs at Lilly. The company's 2023 regulatory submissions will involve empagliflozin for chronic kidney disease (CKD) in Japan, Europe, and the USA; donanemab for early Alzheimer's disease (A.D.) in Japan, U.S., and Europe; tirzepatide for obesity; lebrikizumab for atopic dermatitis in Japan.

Renal Cancer Drugs Market Segment Insights

The renal cancer drugs market is segmented on the basis of therapeutic class, pharmacologic class, type, and end-user. 

Renal Cancer Drugs Therapeutic Class Insights

The renal cancer drugs market, by therapeutic class, is categorized into targeted therapy and immunotherapy. 

Renal Cancer Drugs Pharmacologic Class Insights

On the basis of pharmacologic class, the market is segmented into angiogenesis inhibitors, mTOR inhibitors, monoclonal antibodies and cytokine immunotherapy (IL-2). On the basis of type, the market is segmented into the clear cell, papillary, chromophobe, oncocytic, collecting duct and other. 

Renal Cancer Drugs End-User Insights

On the basis of end-user, the market is segmented hospitals and clinics, ambulatory surgical centers, diagnostic centers, research centers and other.

Renal Cancer Drugs Regional Insights

On the basis of region, the renal cancer drugs market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas is sub-segmented into North America and South America. The North American region is further segmented into the US and Canada. The European region is divided into two, namely, Western Europe and Eastern Europe. Western Europe is further classified into Germany, Italy, France, the UK, Spain, and the rest of Western Europe. The Asia-Pacific region is sub-segmented into Japan, China, India, Australia, the Republic of Korea, and the rest of Asia-Pacific. The Middle Eastern and African region is sub-segmented into the United Arab Emirates, Saudi Arabia, Oman, Kuwait, Qatar, and the rest of the Middle East and Africa.

Regional Market Summary

Global Renal Cancer Drugs Market Share (%), by Region, 2017

Sources: National Cancer Institute, Cancer Research UK, the American Cancer Society, Inc, US Department of Health and Human Services National Institutes of Health

It is estimated that North America dominated the global renal cancer drugs market owing to the increasing innovations in clinical practice, cancer research, and access to cancer treatment in this region. The American Cancer Society estimated about 22,660 women and 42,680 men new cases of kidney cancer in 2018 in the US This influences the market growth in North America.

Europe stood the second largest in the renal cancer drugs market owing to the increasing use of smoking and increasing tobacco usage. According to the World Health Organization’s (WHO) Fact Sheet on Tobacco and Oral Health (2018), Europe has the highest prevalence of smoking among adult population that is 28% of adults in Europe are engaged in smoking. Such a high prevalence of tobacco smoking in this region facilitates the market growth.

Asia-Pacific was projected to be the fastest growing region for the global renal cancer drugs market in 2017. The market is expected to witness growth owing to the rising prevalence of kidney cancer, changing lifestyle, and increasing tobacco use within the population. Such a high prevalence of oral cancer favors the market growth in this region. According to the National Center for Biotechnology Information, August 2016, report 121, 099 renal cancer cases were recorded in Asian countries in 2012, the number is expected to grow in coming years. This influences the market growth in this region.

The Middle East and Africa holds the least share in the global renal cancer drugs market due to the presence of poor health expenditure, low awareness, and economically diverse countries. However, the market is expected to witness growth due to increasing cancer care programs in the Middle East.

Market Segmentation and Key Market Players

Some of the key players in the global renal cancer drugs market are

• Novartis AG (Switzerland)


• Pfizer Inc. (US)


• GlaxoSmithKline plc (UK)


• Genentech, Inc. (US)


• F. Hoffmann-La Roche AG (Switzerland)


• Cipla Limited (India)


• Active Biotech AB (Sweden)


• Amgen (US)


• Bayer AG (Germany)


• Bristol-Myers Squibb company (US).

Renal Cancer Drugs Market Segmentation

Renal Cancer Drugs Therapeutic Class Outlook

• Targeted Therapy


• ImmunoTherapy

Renal Cancer Drugs Pharmacologic Class Outlook

• Angiogenesis Inhibitors


• mTOR Inhibitors


• Monoclonal Antibodies


• Cytokine Immunotherapy (IL-2)

Renal Cancer Drugs Type Outlook

• Clear Cell


• Papillary


• Chromophobe


• Oncocytic


• Collecting Duct


• Othes

Renal Cancer Drugs End-Users Outlook

• Hospitals and clinics


• Ambulatory surgical centers


• Diagnostic centers


• Research centers


• Others

Renal Cancer Drugs Region Outlook

• Americas


• Europe


• Asia-Pacific


• Middle East & Africa